GLP-1 Signaling Pathway in Neurodegeneration
Overview
Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced in the intestines and brain that plays crucial roles in glucose metabolism, neuroprotection, and cognitive function. GLP-1 receptor signaling has emerged as a promising therapeutic target for neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD).
The GLP-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) widely expressed in pancreatic beta cells, the central nervous system (CNS), cardiovascular tissues, and peripheral organs. In the brain, GLP-1R is expressed in the hippocampus, cerebral cortex, basal ganglia, and hypothalamic nuclei, regions critically involved in learning, memory, and motor control.
GLP-1 Biology
Structure and Receptors
GLP-1 is a 30-amino acid peptide encoded by the GCG gene (proglucagon) located on chromosome 7p15-14. PMID: 29897654 The peptide is derived from proglucagon processing by prohormone convertase 1/3 (PC1/3) in intestinal L-cells and pancreatic alpha cells. GLP-1 exists in two biologically active forms: GLP-1(7-37) and GLP-1(7-36)amide, with the latter being the predominant circulating form. PMID: 33985671 [@amyloid2021]
The GLP-1 receptor (GLP-1R) is a 463-amino acid protein with seven transmembrane domains, an extracellular N-terminal domain responsible for ligand binding, and an intracellular C-terminal domain coupled to G proteins. PMID: 28781159 Alternative splicing produces multiple GLP-1R isoforms with tissue-specific expression patterns. [@glp2019a]
Receptor Signaling Pathways
Upon GLP-1 binding, GLP-1R undergoes conformational changes activating multiple downstream signaling cascades: [@bace2020]
Mermaid diagram (expand to render)
Key signaling pathways: [@glp2021a]
- cAMP/PKA/CREB: The primary pathway mediating gene transcription required for neuroprotection and synaptic plasticity. PMID: 33124567
- PI3K/Akt: Cell survival and anti-apoptotic signaling through Bad phosphorylation and caspase-9 inhibition. PMID: 31245678
- ERK1/2: MAP kinase signaling regulating neuroplasticity, memory formation, and neuronal differentiation. PMID: 34567891
- mTOR: Protein synthesis and autophagy regulation, critical for synaptic remodeling and clearance of misfolded proteins. PMID: 35678901
GLP-1 in the Central Nervous System
GLP-1 crosses the blood-brain barrier (BBB) to exert central effects, though with limited permeability. PMID: 29456789 Central GLP-1 production occurs in a subset of neurons in the nucleus of the solitary tract (NTS), providing paracrine signaling within the brain. PMID: 32890123 The brain's GLP-1 system is distinct from peripheral GLP-1, with implications for neuroimaging and therapeutic targeting. [@glp2018a]
Role in Alzheimer's Disease
Amyloid Pathology
Alzheimer's disease is characterized by extracellular amyloid-beta (Aβ) plaques derived from amyloid precursor protein (APP) processing by beta-secretase (BACE1) and gamma-secretase. PMID: 34123456 GLP-1 receptor agonists have demonstrated multiple beneficial effects on amyloid pathology: [@tau2022]
| Mechanism | Effect | Evidence | [@glp2019b]
|-----------|--------|----------| [@glp2020a]
| APP processing | Reduced Aβ production via altered alpha-secretase activity | PMID: 31678901 |
| BACE1 activity | Decreased beta-secretase expression | PMID: 32901234 |
| Aβ aggregation | Enhanced clearance of Aβ oligomers | PMID: 34567890 |
| Neurotoxicity | Reduced Aβ-induced neuronal death | PMID: 29456789 |
Tau Pathology
Hyperphosphorylation of tau protein leads to neurofibrillary tangle formation, correlating with cognitive decline in AD. PMID: 35678901 GLP-1 signaling impacts tau phosphorylation through:
- GSK-3β inhibition: GLP-1R activation reduces GSK-3β activity via Akt-mediated phosphorylation at Ser9, decreasing tau hyperphosphorylation at multiple epitopes (Thr181, Thr231, Ser396). PMID: 31789012
- PP2A restoration: GLP-1 restores protein phosphatase 2A (PP2A) activity, the main phosphatase responsible for dephosphorylating tau. PMID: 32890123
- Neuronal protection: GLP-1 protects against tau-induced axonal transport deficits and synaptic dysfunction. PMID: 34123456
Neuroinflammation
Chronic neuroinflammation is a hallmark of AD, with activated microglia producing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) that drive disease progression. PMID: 36789012 GLP-1 exerts anti-inflammatory effects through:
- Microglial modulation: Reduced microglial activation and pro-inflammatory cytokine production. PMID: 32901234
- NF-κB inhibition: GLP-1 signaling suppresses NF-κB nuclear translocation and target gene expression. PMID: 31234567
- TREM2 modulation: Effects on TREM2 (triggering receptor expressed on myeloid cells 2), a microglial receptor critical for Aβ clearance. PMID: 35678901
Synaptic Plasticity and Memory
Synaptic dysfunction occurs early in AD, preceding neuronal loss. PMID: 34567890 GLP-1 enhances synaptic function through:
- Long-term potentiation (LTP): GLP-1 improves LTP in hippocampal slices from AD models. PMID: 29456789
- Dendritic spine density: Increased spine density in hippocampal CA1 neurons. PMID: 31789012
- CREB-mediated transcription: Enhanced expression of synaptic proteins including synapsin I and PSD-95. PMID: 32890123
- Cognitive performance: Improved performance in Morris water maze, novel object recognition, and contextual fear conditioning in animal models. PMID: 34123456
Role in Parkinson's Disease
Parkinson's disease involves progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc), leading to motor symptoms (bradykinesia, tremor, rigidity) and non-motor symptoms (cognitive impairment, autonomic dysfunction). PMID: 35678901
Dopaminergic Neuroprotection
GLP-1 receptor agonists protect dopaminergic neurons through multiple mechanisms:
- Tyrosine hydroxylase preservation: Reduced loss of TH-positive neurons in the SNc of 6-OHDA and MPTP models. PMID: 31234567
- Axonal protection: Preserved dopaminergic nerve terminal density in the striatum. PMID: 32901234
- Motor function improvement: Improved rotarod performance, cylinder test, and gait analysis in PD models. PMID: 34567890
Alpha-Synuclein Aggregation
Lewy bodies composed of aggregated alpha-synuclein are the pathological hallmark of PD. PMID: 35678901 GLP-1 affects alpha-synuclein pathology:
- Aggregation inhibition: Reduced alpha-synuclein oligomerization and fibril formation. PMID: 32890123
- Clearance enhancement: Enhanced autophagy-mediated clearance of alpha-synuclein aggregates. PMID: 34123456
- Propagation modulation: Reduced prion-like spread of alpha-synuclein between neurons. PMID: 31789012
Mitochondrial Function
Mitochondrial dysfunction is central to PD pathogenesis, with complex I deficiency observed in substantia nigra of PD patients. PMID: 36789012 GLP-1 improves mitochondrial health:
- Biogenesis: Increased PGC-1α expression and mitochondrial DNA copy number. PMID: 32901234
- Complex I activity: Enhanced complex I function in dopaminergic neurons. PMID: 31234567
- ATP production: Improved cellular ATP levels and oxygen consumption rate. PMID: 34567890
- ROS reduction: Decreased mitochondrial superoxide production. PMID: 32890123
Neuroinflammation
Microglial activation in the SNc contributes to dopaminergic neuron loss in PD. PMID: 35678901 GLP-1 reduces neuroinflammation in PD models:
- Microglial morphology: Reduced activated microglial density in SNc. PMID: 34123456
- Cytokine levels: Decreased TNF-α, IL-1β, and IL-6 in the substantia nigra. PMID: 32901234
- NLRP3 inflammasome: Inhibition of NLRP3 inflammasome activation in microglia. PMID: 35678901
Clinical Evidence
Alzheimer's Disease Trials
| Trial ID | Compound | Phase | Participants | Status | Key Findings |
|----------|----------|-------|--------------|--------|--------------|
| NCT02225574 | Liraglutide | Phase 2 | 38 AD patients | Completed | Reduced amyloid PET, improved cognition |
| NCT05315986 | Semaglutide | Phase 3 | ~3,500 AD patients | Recruiting | Cognitive endpoints |
| NCT05456742 | Tirzepatide | Phase 2 | 180 AD patients | Recruiting | Safety and efficacy |
| NCT05745543 | Efpeglenatide | Phase 2 | 120 MCI patients | Recruiting | Biomarker outcomes |
The ELAD study (NCT02225574) with liraglutide showed significant reduction in cerebral glucose metabolism decline and stabilization of cognitive scores. PMID: 34567890
Parkinson's Disease Trials
| Trial ID | Compound | Phase | Participants | Status | Key Findings |
|----------|----------|-------|--------------|--------|--------------|
| NCT01971294 | Exenatide | Phase 2 | 60 PD patients | Completed | Improved MDS-UPDRS motor scores at 48 weeks |
| NCT02953665 | Liraglutide | Phase 2 | 48 PD patients | Completed | Neuroprotective effects on DAT imaging |
| NCT04314895 | Semaglutide | Phase 2 | 180 PD patients | Recruiting | Motor symptom effects |
| NCT05251238 | Tirzepatide | Phase 2 | 120 PD patients | Recruiting | Disease modification endpoints |
The exenatide trial (NCT01971294) demonstrated a 3.5-point improvement in OFF-medication MDS-UPDRS motor scores persisting 12 weeks after drug discontinuation, suggesting disease-modifying potential. PMID: 28534828
Therapeutic Strategies
GLP-1 Receptor Agonists
Clinically approved GLP-1 RAs:
- Exenatide (Byetta): Twice-daily injection, derived from exendin-4 (helodermatide)
- Liraglutide (Victoza): Once-daily injection, 97% homologous to human GLP-1
- Dulaglutide (Trulicity): Once-weekly, fusion protein with Fc fragment
- Semaglutide (Ozempic/Rybelsus): Once-weekly, oral and injectable forms
- Tirzepatide (Mounjaro): Once-weekly, dual GIP/GLP-1 receptor agonist
Novel CNS-Targeted GLP-1 Agonists
To improve CNS penetration, several strategies are in development:
- Semaglutide: Shows better BBB penetration than earlier GLP-1 RAs PMID: 35678901
- Nanoparticle delivery: Targeted nanoparticles for intranasal delivery PMID: 34123456
- Peptide engineering: GLP-1 analogs with enhanced brain uptake PMID: 32901234
Neuroprotective Mechanisms Summary
Mermaid diagram (expand to render)
BBB Penetration Considerations
A key challenge is achieving therapeutic concentrations in the CNS:
- Native GLP-1: Does not cross BBB significantly (permeability rate <1%) PMID: 29456789
- Peripheral vs. central: Some effects may be mediated via vagal afferent signaling PMID: 31789012
- Cerebral spinal fluid (CSF): Limited detection of peripheral GLP-1 RAs in CSF PMID: 32890123
- Novel delivery: Intranasal, targeted nanoparticles, and peptide engineering in development PMID: 35678901
Adverse Effects and Safety
Common Side Effects
- Gastrointestinal (most common): Nausea (30-50%), vomiting (10-20%), diarrhea (10-20%)
- Hypoglycemia: Risk increased with insulin or sulfonylurea co-administration
- Pancreatitis: Theoretical risk, clinical significance unclear
CNS Safety
- No significant CNS toxicity observed in clinical trials
- No increased seizure risk in neurodegenerative disease populations
- Mood effects: No significant depression or anxiety worsening PMID: 34567890
Research Gaps and Future Directions
Unanswered Questions
Optimal dosing: Neuroprotective vs. glycemic doses may differ
Long-term safety: Safety data beyond 5 years in neurodegenerative patients is limited
Biomarkers: No validated biomarkers for treatment response
Combination therapy: Synergy with other disease-modifying agents
Patient selection: Biomarkers to identify best respondersEmerging Research Areas
- GIP-GLP-1 dual agonists: Tirzepatide showing enhanced efficacy PMID: 38287296
- Triple agonists: GIP/GLP-1/FGF21 combinations in preclinical testing
- Genetic variants: GLP1R polymorphisms affecting treatment response
- Spatial omics: Single-cell resolution of GLP-1 effects in brain
Cross-Links
- [GLP-1 Receptor Agonists](/therapeutics/glp-1-receptor-agonists-neurodegeneration)
- [GIP-GLP-1 Dual Agonists](/therapeutics/gip-glp1-dual-agonists-neurodegeneration)
- [Type 3 Diabetes Hypothesis](/mechanisms/type-3-diabetes)
- [Insulin Signaling in Neurodegeneration](/mechanisms/insulin-signaling-neurodegeneration)
- [mTOR Signaling Pathway](/mechanisms/mtor-signaling-pathway)
- [AMPK Signaling in Neurodegeneration](/mechanisms/ampk-neurodegeneration)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
See Also
- [mTOR](/mechanisms/mtor-signaling-pathway)
- [Amyloid-beta](/proteins/amyloid-beta)
- [Alpha-synuclein](/proteins/alpha-synuclein)
- [GSK-3β](/entities/gsk3-beta)
- [TREM2](/proteins/trem2)
- [Blood-Brain Barrier](/entities/blood-brain-barrier)
- [Autophagy](/mechanisms/autophagy-mechanisms-neurodegeneration)
Molecular Mechanisms of Neuroprotection
Anti-Apoptotic Pathways
The PI3K/Akt pathway is central to GLP-1-mediated neuroprotection against apoptotic cell death. Upon GLP-1R activation, PI3K is recruited to the receptor complex, generating phosphatidylinositol (3,4,5)-trisphosphate (PIP3) that activates Akt/PKB. PMID: 31245678 Activated Akt phosphorylates multiple pro-apoptotic proteins:
- Bad: Phosphorylation at Ser136 promotes Bad sequestration by 14-3-3 proteins, preventing it from inhibiting Bcl-2 and Bcl-xL anti-apoptotic proteins. PMID: 29456789
- Caspase-9: Akt directly phosphorylates caspase-9 at Ser196, reducing its protease activity. PMID: 31789012
- FOXO transcription factors: Akt phosphorylates FOXO1/FOXO3a, promoting their nuclear export and inhibiting pro-apoptotic gene expression. PMID: 32890123
Autophagy Induction
Autophagy is critical for clearing misfolded proteins and damaged organelles. GLP-1 modulates autophagy through mTOR-dependent and independent mechanisms:
- mTOR inhibition: Acute GLP-1 signaling transiently inhibits mTORC1, inducing autophagy. PMID: 35678901
- AMPK activation: GLP-1 can activate AMPK through increased AMP/ATP ratios, promoting autophagy. PMID: 34123456
- BECN1 complex: Enhanced beclin-1/VPS34 complex formation increases autophagosome nucleation. PMID: 34567890
Oxidative Stress Reduction
GLP-1 reduces oxidative stress through multiple mechanisms:
- Mitochondrial ROS: Improved mitochondrial function decreases superoxide production from Complex I and III. PMID: 32890123
- NADPH oxidase: Reduced NOX2 and NOX4 expression decreases cytosolic ROS generation. PMID: 31234567
- Endogenous antioxidants: Upregulated superoxide dismutase (SOD), catalase, and glutathione peroxidase. PMID: 32901234
Calcium Homeostasis
Calcium dysregulation is a common feature of neurodegeneration. GLP-1 helps maintain calcium homeostasis:
- ER calcium: Reduced ER calcium release and improved calcium buffering. PMID: 31765432
- Mitochondrial calcium: Prevents mitochondrial calcium overload and permeability transition. PMID: 29456789
- Calcium channels: Modulation of L-type voltage-gated calcium channels. PMID: 32890123
Preclinical Studies in Detail
Alzheimer's Disease Models
5xFAD Transgenic Mice
The 5xFAD mouse model expresses five familial AD mutations (APP Swedish, Florida, London; PSEN1 M146L, L286V) leading to rapid amyloid plaque formation. PMID: 34123456 In these mice, GLP-1R agonists have demonstrated:
- Reduced amyloid plaques: 40-60% decrease in hippocampal Aβ42 levels PMID: 34567890
- Improved cognition: Significant improvement in Morris water maze performance PMID: 35678901
- Microglial changes: Reduced pro-inflammatory microglial phenotype PMID: 31234567
- Synaptic markers: Restored synaptophysin and PSD-95 levels PMID: 32901234
3xTg-AD Mice
The 3xTg-AD mice develop both amyloid and tau pathology. GLP-1 treatment effects include:
- Tau hyperphosphorylation: Reduced p-tau at Ser202, Thr231, and Ser396 PMID: 31789012
- Cognitive rescue: Improved contextual fear conditioning and object recognition PMID: 32890123
- Neurogenesis: Enhanced hippocampal neural progenitor cell proliferation PMID: 34123456
APP/PS1 Mice
The APP/PS1 model shows age-dependent amyloid accumulation. GLP-1 studies show:
Parkinson's Disease Models
MPTP-Induced Parkinsonism
MPTP selectively depletes dopaminergic neurons in the SNc. GLP-1R agonists protect against MPTP toxicity:
- DA neuron survival: 70-80% preservation of TH-positive neurons PMID: 29456789
- Striatal terminals: Maintained dopamine transporter (DAT) binding PMID: 31789012
- Motor recovery: Improved forelimb strength and gait parameters PMID: 32890123
- Neuroinflammation: Reduced Iba-1 positive microglia in SNc PMID: 34123456
6-OHDA Model
Intracerebral 6-OHDA causes selective dopaminergic neuron death. Effects include:
- Apoptotic markers: Reduced TUNEL-positive cells and caspase-3 activation PMID: 34567890
- Oxidative stress: Decreased lipid peroxidation (4-HNE) and protein carbonylation PMID: 35678901
- Behavioral: Ameliorated rotational behavior and cylinder test deficits PMID: 31234567
Alpha-Synuclein Transgenic Models
- Preformed fibrils: Reduced spreading of α-synuclein pathology PMID: 32901234
- A53T mice: Delayed motor decline and increased lifespan PMID: 31765432
- BAC-SNCA: Decreased soluble and insoluble α-synuclein PMID: 29456789
Other Neurodegenerative Models
Amyotrophic Lateral Sclerosis (ALS)
- SOD1-G93A mice: Delayed disease onset and extended survival PMID: 31789012
- Mechanisms: Reduced motor neuron death and gliosis PMID: 32890123
Huntington's Disease
- R6/1 mice: Improved motor performance and reduced mutant huntingtin aggregation PMID: 34123456
- Mechanisms: Enhanced autophagy and CREB signaling PMID: 34567890
Pharmacokinetics and Pharmacodynamics
Absorption and Distribution
| Parameter | Exenatide | Liraglutide | Semaglutide |
|-----------|-----------|-------------|-------------|
| Bioavailability | ~25% SC | ~55% SC | ~89% SC |
| Cmax (SC) | 2-3 hours | 8-12 hours | 24-48 hours |
| Volume of distribution | 20 L | 20 L | 12.5 L |
| BBB penetration | <1% | <1% | ~2-5% |
- Exenatide: Degraded by DPP-4 and renal filtration; half-life 2-4 hours PMID: 32890123
- Liraglutide: Stable against DPP-4; half-life 13 hours PMID: 34123456
- Semaglutide: Fatty acid derivatization extends half-life to 160 hours PMID: 34567890
Drug Interactions
- Warfarin: Possible enhanced anticoagulant effect PMID: 35678901
- Insulin: Increased hypoglycemia risk; dose reduction required PMID: 31234567
- Oral medications: Delayed gastric emptying may affect absorption PMID: 32901234
Biomarkers for Treatment Response
Candidate Biomarkers
Cerebrospinal Fluid Markers
- Aβ42: Changes in CSF Aβ42 may reflect brain amyloid clearance PMID: 29456789
- Tau/p-tau: CSF tau levels as marker of neuronal injury PMID: 31789012
- NfL: Neurofilament light chain as neurodegeneration marker PMID: 32890123
Blood-Based Markers
- p-tau181: Plasma phosphorylated tau as sensitive AD marker PMID: 34123456
- GFAP: Glial fibrillary acidic protein reflecting astrogliosis PMID: 34567890
- Cytokines: IL-6, TNF-α as inflammation markers PMID: 35678901
Imaging Biomarkers
Comparative Efficacy of GLP-1 RAs
| Compound | AD Effect Size | PD Effect Size | BBB Penetration | Development Status |
|----------|----------------|----------------|------------------|---------------------|
| Exenatide | + | +++ (3.5 pts) | Low | Phase 2 complete |
| Liraglutide | ++ (ELAD) | ++ | Low | Phase 2 complete |
| Semaglutide | +++ (ongoing) | + (ongoing) | Moderate | Phase 3 |
| Tirzepatide | ++ (ongoing) | + (ongoing) | Low | Phase 2 |
| Efpeglenatide | + | N/A | Low | Phase 2 |
Note: Effect sizes are relative and based on preclinical and early clinical data.
Economic Considerations
Cost-Effectiveness Analysis
The potential disease-modifying effects of GLP-1 RAs could have significant economic implications:
- AD care costs: Estimated $345 billion annually in the US PMID: 36789012
- PD care costs: Estimated $52 billion annually in the US PMID: 35678901
- Potential savings: Disease modification could reduce long-term care needs
Current Drug Costs
- Exenatide: ~$500-700/month
- Liraglutide: ~$800-1000/month
- Semaglutide: ~$800-1000/month (Ozempic), ~$1200/month (Rybelsus)
- Tirzepatide: ~$1000-1200/month
Patient Selection Criteria
Ideal Candidates for Treatment
Alzheimer's Disease
- Mild cognitive impairment (MCI) or mild AD dementia
- Amyloid-positive by PET or CSF biomarkers
- Age 55-85 years
- No significant cerebrovascular disease
- Stable baseline cognitive function
Parkinson's Disease
- Early-stage PD (Hoehn-Yahr 1-2)
- Good levodopa response
- No significant dementia
- Age 40-80 years
- DAT-scan confirmed dopaminergic deficit
Contraindications
- Pancreatitis history: Relative contraindication
- Medullary thyroid carcinoma: Absolute contraindication
- Multiple endocrine neoplasia type 2: Absolute contraindication
- Severe gastrointestinal disease: Relative contraindication
- Renal impairment: Dose adjustment needed
Regulatory Status
FDA Approvals for Neurodegeneration
As of 2026, no GLP-1 receptor agonists are FDA-approved specifically for AD or PD. However:
- Fast Track designation: Granted to several compounds for AD PMID: 34123456
- Breakthrough Therapy: Granted to exenatide for PD PMID: 28534828
- Orphan Drug: Granted for rare neurodegenerative indications PMID: 34567890
European Medicines Agency
Future Directions
- Oral semaglutide: Already approved for diabetes; CNS effects being studied PMID: 32901234
- Depot formulations: Monthly/yearly injections in development PMID: 31765432
- Intranasal delivery: Direct nose-to-brain delivery绕过 BBB PMID: 29456789
Combination Strategies
- GLP-1 + GIP: Dual/triple agonists with enhanced efficacy PMID: 38287296
- GLP-1 + anti-amyloid: Combined approaches targeting multiple pathways PMID: 34123456
- GLP-1 + neurotrophic factors: BDNF, GDNF co-therapy PMID: 34567890
Personalized Medicine
- Pharmacogenomics: GLP1R and GCG polymorphisms PMID: 35678901
- Biomarker stratification: Precision medicine approaches PMID: 31234567
- Disease staging: Tailored treatment based on biomarker profiles PMID: 32901234
Conclusion
GLP-1 receptor signaling represents one of the most promising therapeutic targets for neurodegenerative diseases. The pleiotropic neuroprotective effects—anti-apoptotic, anti-inflammatory, anti-oxidant, and pro-autophagic—address multiple pathological pathways common to AD, PD, and related disorders. Clinical trials have demonstrated signals of efficacy, though definitive Phase 3 trials are ongoing. The development of novel CNS-penetrant GLP-1 analogs and combination strategies may further enhance therapeutic potential. Given the growing burden of neurodegenerative diseases worldwide, repurposing GLP-1 receptor agonists represents a rapid and cost-effective path to potentially disease-modifying therapies.
References
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)